molecular
techniqu
becom
indispens
viral
diagnost
current
applic
includ
detect
unknown
viral
infect
clinic
sampl
quantit
monitor
viral
load
genotyp
viral
strain
detect
mutat
viral
genom
associ
viral
resist
proper
sampl
acquisit
sampl
transport
well
accur
dna
rna
isol
prerequisit
reliabl
test
result
molecular
diagnost
viral
infect
inhous
well
commerci
assay
use
amplif
viral
dna
rna
detect
viral
infect
viral
load
monitor
mani
viru
speci
consist
sever
subspeci
genotyp
variant
molecular
variat
taken
account
appli
molecular
diagnost
complic
diagnost
genotyp
detect
mutat
relat
therapi
failur
often
reli
sequenc
although
viral
target
commerci
assay
avail
chapter
applic
describ
molecular
method
becom
import
form
viral
diagnost
molecular
test
result
direct
impact
patient
manag
result
reliabl
standard
reproduc
therefor
qualiti
control
standard
import
issu
past
viral
cultur
techniqu
use
detect
virus
clinic
sampl
cultur
method
replac
molecular
detect
virus
advantag
molecular
detect
compar
viru
cultur
higher
diagnost
sensit
much
shorter
timetoresult
limit
molecular
detect
virus
compar
convent
cultur
assay
detect
known
virus
includ
search
panel
screen
persist
virus
usual
perform
serolog
method
detect
antibodi
howev
indirect
method
detect
infect
usual
correl
sever
diseas
viral
load
gener
accur
indic
sever
infect
molecular
techniqu
quantit
viral
load
monitor
appli
monitor
chronic
infect
measur
effect
antivir
therapi
virus
may
import
detect
presenc
viru
determin
genotyp
strain
specif
resistanceassoci
mutat
chapter
applic
molecular
detect
viral
infect
viral
load
monitor
complex
often
also
less
standard
method
like
genotyp
resist
test
clinic
diagnost
discuss
viral
diagnost
perform
wide
rang
clinic
materi
includ
edta
plasma
whole
blood
faec
respiratori
genit
swab
cerebrospin
fluid
liquor
urin
tissu
sampl
biopsi
bronchoalveolar
lavag
fluid
etc
extract
viral
dna
rna
critic
step
whole
procedur
viral
diagnost
materi
pretreat
sampl
necessari
disrupt
tissu
releas
viru
deactiv
inhibitori
factor
inhibitori
factor
pcr
instanc
bile
faec
haemoglobin
blood
sampl
virus
stabl
clinic
materi
process
within
sever
hour
ensur
optim
test
result
especi
case
viral
load
determin
accur
time
sampl
process
essenti
appli
instanc
hiv
viral
load
test
plasma
buffer
develop
sampl
type
eg
faecal
sampl
preserv
nucleic
acid
present
sampl
swab
extract
tube
avail
swab
place
directli
preserv
nucleic
acid
case
tissu
sampl
biopsi
tissu
disrupt
releas
viral
dna
rna
eg
sonic
freez
special
dna
isol
kit
tissu
etc
extract
viral
nucleic
acid
done
manual
automat
commerci
manufactur
develop
number
manual
extract
kit
kit
vari
method
use
time
requir
extract
sampl
suitabl
cost
method
dna
rna
bound
solid
phase
glass
fibr
silica
wash
releas
precipit
manual
extract
requir
multipl
manipul
increas
number
sampl
autom
extract
indispens
diagnost
laboratori
autom
extract
instrument
manufactur
number
differ
compani
autom
standard
recoveri
dna
rna
clinic
sampl
consist
reproduc
sampl
process
within
shorter
period
time
compar
manual
isol
depend
capac
instrument
sever
molecular
techniqu
use
detect
virus
wide
use
targetamplif
method
base
revers
transcriptas
polymeras
chain
reaction
rt
pcr
targetamplif
method
nucleic
acid
sequenc
base
amplif
nasba
transcriptionmedi
amplif
tma
nasba
tma
isotherm
targetamplif
techniqu
describ
chap
volum
techniqu
base
signalamplif
one
techniqu
brancheddna
bdna
assay
techniqu
base
bind
denatur
target
dna
rna
sequencespecif
captur
probe
bound
micro
well
captur
extend
second
probe
call
label
extend
also
bind
specif
includ
sequenc
also
bind
preamplifi
probe
multipl
amplifi
bind
preamplifi
probe
amplifi
signal
techniqu
also
describ
chap
volum
advantag
signal
amplifi
techniqu
method
sensit
specif
obtain
quantit
result
autom
howev
techniqu
avail
target
like
hiv
hepat
b
c
suitabl
develop
laboratori
popular
techniqu
mani
virolog
laboratori
probabl
realtim
pcr
qpcr
commerci
avail
qpcr
base
techniqu
mainli
develop
frequent
detect
target
diagnost
laboratori
advantag
qpcr
molecular
diagnost
virolog
laboratori
laboratori
develop
test
target
cemark
vitro
diagnost
ivd
assay
avail
qpcr
use
qualit
quantit
detect
virus
multiplex
qpcr
use
detect
mani
differ
virus
one
assay
exampl
detect
respiratori
virus
like
influenza
viru
parainfluenza
viru
rhinoviru
respiratori
syncyti
viru
human
metapneumo
viru
coronavirus
respiratori
viral
panel
sampl
patient
respiratori
diseas
detect
noroviru
rotaviru
enterovirus
parechoviru
gastrointestin
viral
panel
patient
gastrointestin
diseas
recent
year
attent
paid
workflow
optim
result
process
order
decreas
number
manual
action
diminish
deviat
error
increas
standard
autom
target
sequenc
design
primer
probe
detect
virus
must
uniqu
target
prefer
pcr
primer
abl
identifi
target
region
high
effici
specif
see
vol
chap
develop
primer
probe
detect
virus
howev
variat
viral
genom
taken
account
especi
rnavirus
lack
proofread
replic
viru
high
variabl
search
dna
databas
nation
center
biotechnolog
inform
ncbi
databas
http
wwwncbinlmnihgovblast
may
reveal
crossreact
nucleotid
sequenc
clinic
applic
necessari
valid
assay
clinic
materi
appli
instanc
faecal
sampl
confirm
absenc
cross
reactiv
normal
flora
specif
sampl
mutat
viral
genom
situat
bind
region
primer
probe
affect
bind
effici
primer
probe
consequ
influenc
effici
amplif
reaction
locat
mutat
number
mutat
import
bind
primer
probe
amplif
effici
detect
virus
primer
probe
prefer
design
anneal
conserv
region
viral
genom
variabl
part
viral
genom
usual
code
protein
target
immun
system
envelop
protein
structur
protein
obvious
primer
probe
design
target
variabl
area
greater
chanc
miss
variant
multipl
target
must
detect
one
clinic
sampl
within
one
pcr
run
primer
probe
use
bind
similar
pcr
condit
temperatur
concentr
etc
design
primer
probe
import
selfand
crosshybrid
avoid
pcr
reaction
perform
onetub
difficult
combin
differ
pcr
reaction
factor
must
taken
account
comprehens
test
mandatori
use
patient
diagnost
see
vol
chap
much
literatur
avail
effect
mismatch
primer
amplificationeffici
mismatchtoler
depend
type
mismatch
ta
gc
primer
percentag
gc
compar
effect
mutat
qpcr
effici
also
depend
number
locat
mutat
mutat
target
dna
end
primer
site
elong
start
may
compromis
elong
pcr
effici
vol
sect
effect
mismatch
investig
directli
relat
nucleotid
involv
tabl
studi
show
mutat
primer
polymeras
start
elong
lead
suboptim
amplif
effici
underestim
amount
target
mismatch
primer
target
lead
underestim
amount
target
factor
mismatch
result
underestim
factor
target
mismatch
nearli
effect
inhibitori
effect
target
amplif
decreas
mutat
move
primer
disappear
nucleotid
end
effect
mutat
primer
primer
bind
site
also
depend
gc
content
primer
sequenc
eg
gc
content
primer
anneal
temperatur
effect
mutat
also
depend
amplif
enzym
use
mmlvtaq
polymeras
reversetranscriptas
mutat
reverseprim
bind
site
nearli
effect
probabl
low
optim
temperatur
mmlv
activ
revers
transcriptas
compar
amv
optim
temperatur
mutat
forwardprim
bind
site
seem
less
import
rtth
use
polymeras
enzym
also
factor
like
constitu
master
mix
salt
concentr
hot
start
may
affect
influenc
mutat
primer
bind
site
clinic
practic
desir
perform
multipl
pcr
reaction
one
sampl
one
pcr
run
either
multiplex
differ
well
singleplex
mean
beforehand
establish
anneal
temperatur
fix
mg
concentr
primer
select
anneal
optim
temperatur
either
adjust
length
primer
adjust
sequenc
use
nucleotideanalogu
see
vol
chap
probesystem
mostli
use
diagnost
viral
infect
qpcr
hydrolysi
probe
hybridis
probe
hydrolysi
probe
bind
target
sequenc
anneal
phase
probe
design
approx
higher
primer
dna
synthesi
elong
phase
hybrid
probe
reach
amount
pcrproduct
relat
amount
pcr
product
primer
perfect
match
hydrolys
activ
polymeras
break
probe
reporterfluorochrom
vic
fam
tet
etc
quencher
tamra
separ
fluoresc
reson
energi
transfer
fret
signal
report
releas
see
vol
chap
mgbor
lnaprob
type
hydrolysi
probe
frequent
use
qpcr
assay
diagnosi
viral
infect
vol
chap
probe
design
well
allow
three
mismatch
target
sequenc
without
much
loss
signal
applic
mismatchtoler
need
instanc
qpcr
detect
variabl
viral
target
howev
virolog
also
applic
import
molecular
variat
detect
instanc
detect
viral
variant
differ
pathogen
detect
mutat
associ
resist
antivir
medic
depend
purpos
assay
less
mismatch
toler
hybridis
probe
use
viral
diagnost
use
molecular
beacon
molecular
beacon
long
probe
loop
structur
contain
part
probe
bind
target
region
attach
probe
two
gc
rich
complementari
region
creat
hairpin
structur
one
side
probe
label
fluoresc
dye
quencher
probe
releas
fluoresc
signal
upon
hybrid
target
dna
hydrolys
elong
phase
pcr
reaction
molecular
beacon
probe
design
loop
compar
stem
sensit
detect
mutat
exampl
mutat
associ
viral
resist
hybrid
probe
doubl
strand
probe
contain
long
strand
nt
label
report
fluorochrom
short
strand
homolog
report
probe
nt
label
quencher
molecul
elong
report
probe
prefer
bind
target
dna
probe
quencher
releas
therebi
releas
signal
method
allow
detect
signal
much
lower
temperatur
much
less
sensit
mutat
target
sequenc
without
affect
pcr
effici
howev
probe
difficult
design
compar
hydrolysi
probe
import
detect
viru
often
analysi
genotyp
characterist
viru
also
import
within
one
speci
often
strain
differ
characterist
differ
pathogen
need
treatment
strategi
exampl
group
enterovirus
genu
enteroviru
consist
speci
echoviru
rhinoviru
polioviru
enteroviru
coxsackieviru
furthermor
speci
consist
sever
subspeci
strain
viral
diagnost
import
distinguish
instanc
pathogen
polioviru
speci
within
genu
enterovirus
may
also
relev
type
virus
within
speci
done
obtain
inform
relationship
differ
isol
case
outbreak
identifi
strain
increas
virul
epidemiolog
purpos
anoth
exampl
human
papillomaviru
hpv
hpv
associ
cervic
cancer
within
genu
highrisk
hpv
hrhpv
strain
eg
hpv
probabl
hrhpv
strain
eg
hpv
lowrisk
hpv
strain
eg
etc
distinguish
probabl
hrhpv
strain
lowrisk
strain
essenti
clinic
diagnost
anoth
applic
molecular
detect
resist
antivir
medic
field
becom
import
develop
new
antivir
medic
occurr
resist
variant
varieti
virus
exampl
virus
resist
antivir
medic
import
hiv
hepat
b
hepat
c
herp
simplex
viru
type
ii
influenza
viru
techniqu
avail
detect
viral
variat
frequent
use
also
inform
one
sequenc
part
viral
genom
sequenc
use
sever
purpos
like
genotyp
detect
variat
detect
mutat
associ
resist
disadvantag
howev
also
timeconsum
procedur
develop
sequenc
technolog
becom
less
expens
feasibl
diagnost
laboratori
see
vol
chap
sequenc
viral
genom
upload
onlin
databas
eg
ncbi
determin
genotyp
viru
virus
tool
avail
internet
eg
ncbi
genotyp
tool
hivgrad
either
genotyp
quickli
determin
mutat
associ
antivir
resist
tool
avail
virus
virus
sequenc
upload
onlin
databas
compar
viral
sequenc
retriev
genbank
lo
alamo
databas
program
like
ncbi
blast
seqscap
use
compar
sequenc
detect
mutat
case
inform
select
part
genom
mutat
necessari
subtyp
detect
antivir
resist
applic
instanc
genotyp
human
papillomaviru
hpv
hepat
b
hepat
c
detect
drugresist
variant
hepat
b
hybrid
assay
develop
lipa
assay
consist
qpcr
combin
hybrid
assay
vol
chap
hybrid
assay
perform
nitrocellulos
strip
contain
line
load
genotypespecif
oligonucleotid
detect
drugresist
variant
strip
contain
wild
type
mutantspecif
oligonucleotid
probe
advantag
method
compar
sequenc
sampl
process
time
evalu
test
result
less
timeconsum
howev
obviou
disadvantag
mutat
appear
outsid
oligonucleotid
use
assay
detect
newli
emerg
variant
distinguish
furthermor
natur
variat
viru
visibl
sequenc
provid
inform
viral
genom
direct
sequenc
pcr
product
sanger
method
yield
inform
variant
present
low
percentag
total
viral
popul
variant
present
less
total
viral
popul
detect
next
gener
sequenc
method
sensit
detect
minor
viral
popul
lipaassay
also
tend
better
detect
minor
strain
compar
sangersequenc
method
clinic
diagnost
question
often
viru
caus
diseas
use
molecular
diagnost
answer
question
symptom
diseas
patient
characterist
also
give
direct
like
etiolog
agent
instanc
respiratori
diseas
caus
number
virus
like
influenza
parainfluenza
adenoviru
coronavirus
rhinovirus
human
metapneumo
viru
children
respiratori
syncyti
viru
also
common
caus
infect
upper
respiratori
tract
may
differ
caus
infect
lower
respiratori
tract
addit
patientrel
factor
like
asthma
chronic
diseas
medic
may
influenc
type
serious
infect
diagnost
laboratori
diagnost
compani
develop
specif
respiratori
panel
detect
common
caus
respiratori
infect
also
gastroenter
mening
multipl
caus
usual
panel
virus
test
frequent
caus
viral
mening
enterovirus
occasion
viral
mening
caus
virus
like
herp
simplex
viru
mump
viru
arbovirus
may
requir
precaut
treatment
exampl
viral
caus
diseas
shown
tabl
advantag
appli
panel
major
caus
infect
includ
test
singl
assay
disadvantag
infect
specif
patient
includ
assay
patient
may
variant
specif
viru
detect
assay
appli
molecular
techniqu
made
possibl
obtain
quantit
semi
quantit
result
relat
viral
load
obtain
reliabl
quantit
autom
workflow
nucleic
acid
isol
amplif
detect
process
result
essenti
laboratori
maintain
high
degre
standard
ensur
test
result
reproduc
three
major
reason
quantit
detect
viral
dna
rna
first
reason
amount
viru
viral
load
usual
reflect
amount
viral
dna
rna
present
indic
serious
infect
first
demonstr
hiv
use
quantit
bdna
techniqu
increas
amount
rna
genom
plasma
directli
correl
decreas
tcell
diseas
progress
induc
mortal
sinc
find
publish
viral
load
monitor
major
factor
decis
antivir
treatment
sinc
quantit
viral
load
determin
implement
patient
monitor
viral
infect
well
peopl
infect
cytomegaloviru
epstein
barr
viru
virus
usual
caus
problem
occasion
caus
viremia
viru
detect
blood
without
symptom
howev
virus
caus
major
problem
patient
stem
cell
transplant
treatment
virus
instal
certain
viral
load
reach
ebv
shown
viral
load
copiesml
predict
develop
posttranspl
lymphoprolif
diseas
start
antivir
therapi
viral
load
reach
symptom
appear
preemptiv
therapi
shown
ebvrel
mortal
significantli
reduc
patient
second
reason
quantif
viral
dna
rna
risk
viral
transmiss
directli
relat
amount
viru
present
vertic
transmiss
mother
child
pregnanc
birth
exampl
vertic
transmiss
hiv
prevent
either
decreas
viral
load
pregnanc
antivir
therapi
perform
caesarian
section
hepat
b
viru
also
shown
risk
vertic
transmiss
directli
relat
viral
load
mother
infect
prevent
immedi
activ
passiv
vaccin
newborn
howev
risk
vertic
transmiss
still
present
mother
high
viral
load
iuml
case
also
recommend
start
antivir
treatment
last
trimest
pregnanc
altern
case
needl
stick
incid
viral
load
directli
relat
chanc
transmiss
viru
needl
stick
accid
collect
name
incid
health
care
worker
accid
come
contact
patient
fluid
may
contamin
hepat
b
hepat
c
hiv
accident
blood
contact
occur
frequent
hospit
measur
taken
accident
contact
compris
monitor
viral
load
victim
needl
stick
accid
patient
andor
prevent
antivir
treatment
vice
versa
health
care
worker
may
also
infect
patient
sever
countri
taken
measur
prevent
transmiss
viral
infect
patient
hepat
b
sever
case
transmiss
health
care
worker
patient
known
physician
high
hepat
b
viral
load
forbidden
perform
medic
procedur
pose
risk
patient
countri
third
reason
quantif
viral
dna
rna
monitor
effect
antivir
treatment
ultim
goal
antivir
treatment
prevent
damag
host
infect
antivir
treatment
instal
reduc
viral
load
prevent
damag
applic
monitor
effect
antivir
treatment
use
hiv
hepat
b
hepat
c
herp
virus
like
cytomegaloviru
epstein
barr
viru
primari
goal
decreas
viral
load
undetect
limit
monitor
decreas
viral
load
directli
start
therapi
predict
valu
treatment
success
virus
absenc
certain
declin
viral
load
may
indic
stop
switch
treatment
condit
influenc
reliabl
quantif
viral
load
first
sampl
procedur
handl
sampl
may
influenc
test
result
exampl
varicella
zoster
viru
cellassoci
viru
vesicl
fluid
viru
load
low
may
result
falseneg
pcr
test
result
scrape
bottom
vesicl
virusinfect
cell
present
may
result
high
viral
load
second
viral
load
may
fluctuat
much
relat
time
need
gener
quantit
test
result
acut
viral
infect
viru
load
increas
quickli
high
level
decreas
mani
acut
viral
respiratori
infect
possibl
show
relat
viral
load
serious
respiratori
diseas
third
variat
viru
load
caus
procedur
avoid
mani
factor
influenc
outcom
viral
load
sampl
handl
freez
thaw
pipet
deviat
sampl
viscos
batchdiffer
reagent
prepar
pcrkit
etc
obtain
reliabl
quantit
test
result
factor
avoid
autom
quantit
pcr
reduc
analyt
variat
quantit
pcr
assay
viral
load
determin
calibr
use
intern
refer
strain
make
comparison
viral
load
laboratori
assay
reliabl
due
combin
sloppi
replic
immun
pressur
factor
virus
evolv
differ
genoor
subtyp
clinic
featur
genotyp
may
differ
sometim
even
influenc
choic
therapi
viral
resist
occur
treatment
determin
cours
infect
choic
medic
often
small
variat
even
singl
nucleotid
point
mutat
snp
may
great
impact
pathogen
replic
activ
andor
suscept
treatment
mutat
usual
repres
amino
acid
replac
posit
eg
mutat
revers
transcriptas
gene
hiv
glutamin
posit
protein
replac
methionin
exampl
discuss
follow
subsect
antivir
treatment
hiv
consist
combin
antivir
drug
nucleotidenucleosid
revers
transcriptas
inhibitor
nrti
nonnucleotid
revers
transcriptas
inhibitor
nnrti
coreceptor
antagonist
maraviroc
pharmacokinet
booster
agent
like
ritonavir
genotyp
resist
test
usual
perform
revers
transcriptas
proteas
gene
hiv
perform
case
suboptim
viral
reduct
assist
select
activ
drug
mutat
lead
highlevel
reduc
suscept
integras
inhibitor
describ
pretreat
resist
test
advis
due
risk
transmiss
resist
viru
strain
mutat
abl
individu
induc
reduc
suscept
antivir
drug
wherea
mutat
invok
resist
combin
mutat
antihiv
medic
term
lowor
highgenet
barrier
often
use
indic
whether
resist
evolv
easili
requir
one
mutat
resist
usual
test
sequenc
part
genom
variou
onlin
tool
assist
laboratori
worker
analysi
genotyp
test
result
intern
aid
societi
usa
maintain
list
resistanceassoci
mutat
http
wwwiasusaorgresistancemut
login
requir
stanford
univers
maintain
hiv
drug
resist
databas
http
hivdb
stanfordedu
hepat
b
viru
consist
genotyp
h
small
differ
genotyp
respons
differ
risk
develop
liver
carcinoma
respons
treatment
treatment
hepat
b
antivir
medic
aim
longterm
suppress
hepat
b
viru
reduc
relat
morbid
mortal
thu
far
differ
genotyp
shown
minor
consequ
treatment
strategi
interest
predict
instanc
hepat
b
genotyp
b
seem
respond
rel
well
treatment
interferonalpha
compar
instanc
genotyp
c
physician
tend
prefer
treat
genotyp
b
interferon
treatment
interferon
aim
improv
antivir
respons
immun
system
reduc
viral
suscept
cell
enhanc
major
histocompat
complex
mhc
antigen
express
induc
cellular
protein
import
natur
defens
cell
virus
lead
immun
control
chronic
hepat
b
infect
directact
antivir
daa
nucleotideor
nucleosideanalogu
avail
treatment
infect
hepat
b
viru
lamivudin
adefovir
telbivudin
tenofovir
entecavir
one
mutat
call
ymdd
motiv
associ
resist
lamivudin
ymdd
motiv
conserv
sequenc
rnadepend
dna
polymeras
gene
hepat
b
viru
consist
tyrosin
methionin
two
aspart
dd
replac
methionin
isoleucin
yidd
valin
yvdd
lead
resist
sinc
polymeras
hepat
b
surfac
antigen
gene
overlap
replac
nucleotid
may
also
lead
chang
surfac
antigen
therefor
mutat
also
impact
product
secret
hbsag
lamivudin
long
treatment
option
hepat
b
replac
potent
antivir
like
entecavir
tenofovir
entecavir
howev
less
effect
patient
pretreat
lamivudin
carri
ymdd
variant
hepat
b
genotyp
resist
test
hepat
b
perform
sequenc
compar
sequenc
refer
strain
lipa
assay
also
develop
genotyp
detect
mutat
associ
resist
altern
hiv
hepat
b
treatment
aim
longterm
suppress
viru
treatment
hepat
c
viru
aim
total
clear
viru
host
past
decad
hepat
c
treat
combin
interferonalpha
ribavirin
nowaday
increas
number
directact
antivir
daa
avail
sever
viral
protein
involv
hcv
lifecycl
nonstructur
ns
serin
proteas
rnadepend
rna
polymeras
rdrp
protein
target
drug
play
role
format
replic
complex
viru
releas
new
viral
particl
hepat
c
viru
major
genotyp
differ
preval
differ
respons
treatment
genotyp
preval
western
countri
genotyp
perform
lipa
assay
sequencebas
assay
also
develop
firstgener
proteaseinhibitor
telaprevir
boceprevir
activ
hepat
c
genotyp
less
effect
therefor
regist
genotyp
new
regist
treatment
genotyp
polymeras
inhibitor
inhibitor
show
less
genotyp
specif
sinc
treatment
one
antivir
often
ineffect
combin
therapi
alway
given
choic
medicin
larg
depend
hepat
c
genotyp
antivir
resist
appear
seriou
problem
treatment
polymeraseinhibitor
clinic
relev
mutat
describ
like
mv
drug
resist
proteaseinhibitor
seem
complex
k
mutat
relat
resist
simeprevir
genotyp
patient
fig
kt
mutat
appear
invok
resist
almost
proteaseinhibitor
includ
proteaseinhibitor
still
develop
genotyp
patient
v
mutat
seem
preval
mostli
genotyp
patient
relat
resist
mutat
associ
resist
may
present
treatment
develop
treatment
pretreat
sequenc
analysi
monitor
respons
antivir
treatment
give
inform
may
help
futur
therapi
develop
fig
align
part
hcv
proteas
refer
strain
hcv
gt
nucleotid
amino
acid
detect
drugresist
variant
done
sequencebas
assay
sequenc
variat
genotyp
hepat
c
larg
make
difficult
design
primer
amplif
sequenc
proteas
polymeras
gene
hepat
c
fig
shown
even
within
hepat
c
genotyp
subtyp
consider
sequenc
variat
fig
herp
simplex
viru
hsv
varicella
zoster
viru
vzv
cytomegaloviru
cmv
belong
herp
viru
famili
treat
specif
antivir
drug
resist
describ
famili
virus
sequenc
part
genom
necessari
detect
involv
mutat
hsv
caus
lesion
mouth
usual
harm
howev
lesion
becom
sever
immun
suppress
patient
system
ill
may
occur
hsv
patient
receiv
treatment
acyclovir
similar
medic
like
valaciclovir
famciclovir
becom
resist
resist
acyclovir
associ
mutat
thymidinekinas
gene
viral
thymidinekinas
phosphoryl
acyclovir
necessari
step
antivir
mechan
acyclovir
act
nucleotid
analogu
disturb
viral
dna
synthesi
acyclovirresist
variant
may
still
sensit
foscarnet
foscarnet
block
dna
polymeras
therebi
inhibit
viral
dna
synthesi
mutat
polymerasegen
associ
resist
foscarnet
gene
mani
polymorph
may
present
resist
acyclovir
often
associ
insert
delet
thymidinekinas
gene
also
singl
mutat
associ
resist
thorough
analysi
gene
sequenc
comparison
refer
strain
mutat
found
literatur
necessari
analysi
gene
thymidin
kinas
polymeras
involv
resist
vzv
antivir
therapi
first
infect
varicella
zoster
viru
give
chickenpox
varicella
zoster
viru
remain
latent
present
neural
axon
central
nervou
system
reactiv
caus
shingl
treatment
similar
herp
simplex
viru
treatment
acyclovir
foscarnet
resist
test
also
perform
sequenc
part
thymidin
kinas
polymeras
gene
compar
refer
sequenc
first
choic
treatment
cmv
ganciclovir
ganciclovir
guanosin
analogu
exert
antivir
effect
inhibit
cmv
dna
polymeras
ganciclovir
phosphoryl
viral
phosphotransferas
code
cmv
dna
polymeras
product
mutat
gene
lead
resist
howev
mutat
significantli
common
mutat
mutat
associ
higher
level
resist
ganciclovir
crossresist
cidofovir
foscarnet
influenza
member
famili
orthomyxovirida
viru
speci
influenza
influenza
b
influenza
c
caus
classic
flu
influenza
speci
consist
differ
strain
design
accord
structur
haemagglutinin
ha
neuraminidas
na
gene
variabl
viral
protein
involv
attach
target
cell
fusion
endosom
membran
influenza
virus
segment
rnagenom
segment
na
hacod
sequenc
differ
segment
exchang
ha
encod
segment
nr
na
segment
nr
within
influenza
least
haencod
segment
known
segment
number
known
human
variant
navari
recombin
influenza
variant
may
lead
new
combin
hand
ngene
antigen
shift
wherea
mutat
hand
ngene
lead
new
variant
slightli
differ
properti
antigen
drift
antigen
drift
caus
instanc
two
strain
may
slightli
differ
antigen
properti
antigen
drift
less
pathogen
viral
strain
howev
may
lead
pathogen
strain
usual
everi
winter
season
one
domin
influenza
strain
activ
often
one
two
astrain
one
bstrain
within
strain
differ
isol
distinguish
compar
influenza
influenza
b
genet
less
diver
infect
nearli
restrict
human
influenza
b
thought
less
pathogen
influenza
c
far
less
common
influenza
b
caus
sever
ill
incident
associ
outbreak
viral
diagnost
paninfluenza
pcr
use
primer
detect
influenza
speci
matrix
gene
segment
differ
pcr
detect
influenza
b
monitor
influenza
activ
winter
season
estim
effect
vaccin
viral
strain
type
h
ngene
segment
everi
year
type
perform
revers
transcriptas
qpcr
typespecif
primer
probe
commerci
assay
also
avail
strain
type
use
predict
upcom
strain
determin
strain
need
includ
vaccin
viru
mutat
year
year
make
exist
vaccin
ineffect
specif
inform
viru
sequenc
whole
genom
consist
around
nucleotid
within
influenza
strain
differ
isol
distinguish
reveal
highli
variabl
genet
structur
viru
patient
care
strain
type
relat
sensit
antivir
treatment
influenza
b
strain
sensit
oseltamivir
zanamivir
two
neuraminidas
inhibitor
occasion
resist
strain
found
sometim
relat
longterm
treatment
influenza
infect
immunocompromis
patient
resist
oseltamivir
also
report
season
due
mutat
posit
neuraminidas
gene
result
substitut
histidin
tyrosin
strain
mutat
howev
still
suscept
zanamivir
molecular
diagnost
becom
indispens
diagnosi
viral
infect
qpcr
techniqu
use
detect
virus
also
viral
load
determin
wherea
chronic
viral
infect
usual
detect
serolog
method
test
immun
molecular
techniqu
becom
import
monitor
chronic
viral
infect
respons
antivir
treatment
appli
molecular
techniqu
learn
viral
variat
differ
genotyp
exist
within
viru
speci
variat
clinic
impact
virus
specif
mutat
viral
genom
relat
resist
antivir
medic
rapid
cheaper
molecular
techniqu
like
next
gener
sequenc
aid
explor
field
extens
